Table 1

Baseline demographic data, clinical, laboratory and MRI parameters between the two groups

Placebo group (N=12)Etanercept group (N=19)
Baseline
 Age (years)54.9 ± 13.653.0 ± 12.1
 Disease duration (years)11.9 ± 7.711.9 ± 6.7
 Women/men10/217/2
 RF positivity (%)66.778.9
 Anti-CCP positivity (%)66.763.2
 ANA positivity (%)5057.9
Clinical/laboratory parameters
 VAS pain (0−100 mm)43.4 ± 20.459.5 ± 24.1
 DAS28 (ESR based)4.1 ± 0.755.0 ± 1.03
 HAQ score (1−3)0.5 (0.2−0.9)0.85 (0.42−1.36)
 Tender joint count (0−66)3.5 (3−6)4 (1−12)
 Swollen joint count (0−68)3 (2.2−7.5)7 (2−16)
 ESR (mm/h)19.1 ± 9.628.4 ± 13.6
 CRP (mg/dl)0.9 (0.3−1.1)1.7 (0.7−2.9)
MRI parameters
 Synovitis score (0−21)6.5 (5.2−9.0)13.0 (7.0−14.0)
 Bone oedema score (0−69)5.0 (2.0−15.0)15.0 (4.0−22.0)
 Erosion score (0−230)13.0 (7.2−36.5)27.0 (16.0−53.0)
 Tenosynovitis score (0−26)6.0 (5.0−7.7)8.0 (4.0−12.0)
 RAMRIS total (0−320)24.5 (13.7−61.2)59.0 (25.0−90.0)
  • Values are medians (ranges) and mean ± SD.

  • anti-CCP, anti-cyclic-citrullinated peptide antibodies; ANA, antinuclear antibody; CRP, C-reactive protein; DAS28, disease activity score 28-joint assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RAMRIS, Rheumatoid Arthritis Magnetic Resonance Imaging Score; RF, rheumatoid factor (positive >20 IU); VAS, visual analogue scale.